Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 274

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 274
---
1) (2)   |            |     | Pursuant to this 
 Prospectus (2)   |             |     | Number of        
 Shares           |             |     | Percent (3) |      |   |
| Keystone Capital Partners, LLC (4) |     |                    | 41,751,666 |     |                  | 729,596,950 |     |                  | 771,348,616 |     |             | 4.99 | % |

| (1) | Beneficial ownership as reflected                                                                                                           
 in this table reflects the total number of shares potentially issuable underlying the Preferred Shares and Warrants, and does not give      
 effect to the various limitations on the conversion of the Preferred Shares and exercise of the Warrants. Accordingly, actual beneficial    
 ownership, as calculated in accordance with Section 13(d) and Rule 13d-3 thereunder may be lower than as reflected in the table. The        
 number of shares of Common Stock beneficially owned after the offering assumes the sale of all shares being offered pursuant to this        
 prospectus. In accordance with Rule 13d-3(d) under the Exchange Act, we have excluded from the number of shares beneficially owned prior    
 to the offering all of the shares that Selling Securityholder may be required to purchase under the respective Purchase Agreements, because 
 the issuance of such shares is solely at our discretion and is subject to conditions contained in the Purchase Agreements, the satisfaction 
 of which are entirely outside of Selling Securityholder’s control, including the registration statement that includes this prospectus       
 becoming and remaining effective. Furthermore, the Fixed Purchases, VWAP Purchases, or Additional VWAP Purchases, as applicable, of Common  
 Stock are subject to certain agreed upon maximum amount limitations set forth in the Purchase Agreements.                                   |

| (2) | This table assumes the conversion of the Series A Preferred Stock at an effective conversion price, giving effect to applicable multipliers and adjustments, of $0.05 per share, the Series C Preferred Stock at an effective conversion price, giving effect to applicable multipliers and adjustments, of $0.05 per share, the Series D Preferred Stock, at an effective conversion price, giving effect to applicable multipliers and adjustments, of $0.05 per share, and the Series E Preferred Stock, at an effective conversion price of $4.1625 per share. Because the conversion price of the Preferred Shares may be adjusted, the number of shares that will actually be issued may